title: Tolterodine for the treatment of overactive bladder: a review.
abstract: Overactive bladder (OAB) is a prevalent condition. Numerous clinical trials have demonstrated the efficacy and safety of immediate release tolterodine in the treatment of OAB in different patient populations. This review details the characteristics, clinical efficacy and safety of extended release (ER) tolterodine. This formulation yields a flatter serum concentration profile and provides clinically meaningful symptom improvement as early as week 1 of treatment. Tolterodine ER is effective in diverse patient populations with varying levels of symptom severity, and efficacy is maintained with long-term treatment. Tolterodine is an effective, safe, and convenient treatment option for long-term relief of OAB symptoms.
authors.affiliation: Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB644, Charleston, SC 29425, USA. rovnere@musc.edu
authors.forename: Eric S
authors.initials: ES
authors.lastname: Rovner
mesh_terms: D001559:Benzhydryl Compounds / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003408:Cresols / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068737:Tolterodine Tartrate; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate